The chronic gap between laboratory promise and clinical success in neurodegenerative disease treatment may be narrowing, thanks to a new generation of three-dimensional brain models that more faithfully replicate human neural biology than any prior in vitro system. For the roughly 50 million people worldwide living with Alzheimer's, Parkinson's, or Huntington's disease, improved preclinical tools represent a meaningful step toward treatments that actually translate from bench to bedside.
This review in Molecular Biology Reports synthesizes recent progress in neural organoid and assembloid research, highlighting how induced pluripotent stem cell (iPSC) technology now allows the generation of patient-derived 3D brain structures that mirror individual genetic disease signatures. These organoids successfully reproduce disease-specific pathological hallmarks — including tau and amyloid aggregation in Alzheimer's models, alpha-synuclein accumulation in Parkinson's models, and mutant huntingtin-driven synaptic disruption in Huntington's models. Critically, they have also functioned as test platforms for adeno-associated viral (AAV) vector gene delivery, exposing serotype-dependent tropism differences and informing vector optimization strategies. Multi-regional assembloids — fused organoid constructs replicating inter-regional communication — add further anatomical and functional complexity.
Organoid modeling occupies a genuinely important transitional niche in translational neuroscience. Traditional animal models, particularly rodents, carry well-documented limitations in recapitulating human-specific neural circuitry and disease progression. iPSC-derived organoids partially bridge this gap, preserving donor-specific genetic backgrounds while eliminating cross-species extrapolation. However, the field faces persistent challenges: organoids currently lack a functional vascular system capable of sustaining larger tissue volumes, exhibit variable differentiation consistency across research groups, and represent developmental — rather than adult — brain states, which limits their direct relevance to late-onset neurodegeneration. The review acknowledges integration of immune and vascular components as an active frontier. From a translational standpoint, the convergence of organoid platforms with AAV gene therapy screening is incrementally valuable rather than paradigm-shifting — the technology refines preclinical validation pipelines but does not yet replace the complexity of whole-organism disease dynamics. Standardization efforts will be pivotal before organoid-derived AAV data meaningfully accelerates regulatory pathways.